Low dose interleukin-11 is well-tolerated and induces platelet responses in myelodysplasia and other bone marrow failure states

R. Kurzrock, J. Cortes, D. Thomas, S. Pilât, M. Talpaz

Research output: Contribution to journalArticle

Abstract

Interleukin-11 (IL-11) is a thrombopoietic cytokine that attenuates post-chemotherapy thrombocytopenia. The dose used post-chemotherapy is = 50 ng/kg/day s.c. Very little is known about the activity of IL-11 in bone marrow failure states. Our preliminary experience with IL-11 at doses of 50 ng/kg/day suggested that bone marrow failure patients developed significant peripheral and pulmonary edema after the prolonged dosing necessary for treating these conditions. We therefore initiated a study of low-dose IL-11 (10 jig/kg/d). Response criteria included doubling of platelets and rise to 50 x lO'/L or tripling of platelets and rise to 20 × 109/L. Sixteen pts are évaluable for response. Their median age was 58 years (range, 5 to 84 years). Six pts had diploid cytogenetics; the others had a variety of chromosomal abnormalities. Six of 16 pts (38%) showed a platelet response to IL-11 and two had a multilineage response (to IL-11 alone (N=l); to IL-11 + G-CSFand EPO (N=l)). Responders included 5 of 11 pts with myelodysplasia (MDS) and 1 of 4 patients with aplastic anemia (AA). Response duration was 12, 13, 14+, 22+, 25 and 30 weeks. Side-effects of IL-11 were mild (peripheral edema, N=7; conjunctival injection, N=7 or myalgia (N=l) (all grade 1). Seven pts had no side-effects. Our pilot study suggests that administration of low dose IL-11 (10μg/kg/day) can raise platelet counts, without significant toxicity, in selected thrombocytopenic patients with bone marrow failure.

Original languageEnglish (US)
Pages (from-to)147a
JournalBlood
Volume96
Issue number11 PART I
StatePublished - Dec 1 2000
Externally publishedYes

Fingerprint

Interleukin-11
Platelets
Bone
Blood Platelets
Bone Marrow
Chemotherapy
Jigs
Drug Therapy
Aplastic Anemia
Myalgia
Pulmonary Edema
Diploidy
Platelet Count
Cytogenetics
Chromosome Aberrations
Thrombocytopenia
Interleukin-10
Toxicity
Edema
Cytokines

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Low dose interleukin-11 is well-tolerated and induces platelet responses in myelodysplasia and other bone marrow failure states. / Kurzrock, R.; Cortes, J.; Thomas, D.; Pilât, S.; Talpaz, M.

In: Blood, Vol. 96, No. 11 PART I, 01.12.2000, p. 147a.

Research output: Contribution to journalArticle

Kurzrock, R. ; Cortes, J. ; Thomas, D. ; Pilât, S. ; Talpaz, M. / Low dose interleukin-11 is well-tolerated and induces platelet responses in myelodysplasia and other bone marrow failure states. In: Blood. 2000 ; Vol. 96, No. 11 PART I. pp. 147a.
@article{e156ace83a174ceb9c7554f936e34fb7,
title = "Low dose interleukin-11 is well-tolerated and induces platelet responses in myelodysplasia and other bone marrow failure states",
abstract = "Interleukin-11 (IL-11) is a thrombopoietic cytokine that attenuates post-chemotherapy thrombocytopenia. The dose used post-chemotherapy is = 50 ng/kg/day s.c. Very little is known about the activity of IL-11 in bone marrow failure states. Our preliminary experience with IL-11 at doses of 50 ng/kg/day suggested that bone marrow failure patients developed significant peripheral and pulmonary edema after the prolonged dosing necessary for treating these conditions. We therefore initiated a study of low-dose IL-11 (10 jig/kg/d). Response criteria included doubling of platelets and rise to 50 x lO'/L or tripling of platelets and rise to 20 × 109/L. Sixteen pts are {\'e}valuable for response. Their median age was 58 years (range, 5 to 84 years). Six pts had diploid cytogenetics; the others had a variety of chromosomal abnormalities. Six of 16 pts (38{\%}) showed a platelet response to IL-11 and two had a multilineage response (to IL-11 alone (N=l); to IL-11 + G-CSFand EPO (N=l)). Responders included 5 of 11 pts with myelodysplasia (MDS) and 1 of 4 patients with aplastic anemia (AA). Response duration was 12, 13, 14+, 22+, 25 and 30 weeks. Side-effects of IL-11 were mild (peripheral edema, N=7; conjunctival injection, N=7 or myalgia (N=l) (all grade 1). Seven pts had no side-effects. Our pilot study suggests that administration of low dose IL-11 (10μg/kg/day) can raise platelet counts, without significant toxicity, in selected thrombocytopenic patients with bone marrow failure.",
author = "R. Kurzrock and J. Cortes and D. Thomas and S. Pil{\^a}t and M. Talpaz",
year = "2000",
month = "12",
day = "1",
language = "English (US)",
volume = "96",
pages = "147a",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "11 PART I",

}

TY - JOUR

T1 - Low dose interleukin-11 is well-tolerated and induces platelet responses in myelodysplasia and other bone marrow failure states

AU - Kurzrock, R.

AU - Cortes, J.

AU - Thomas, D.

AU - Pilât, S.

AU - Talpaz, M.

PY - 2000/12/1

Y1 - 2000/12/1

N2 - Interleukin-11 (IL-11) is a thrombopoietic cytokine that attenuates post-chemotherapy thrombocytopenia. The dose used post-chemotherapy is = 50 ng/kg/day s.c. Very little is known about the activity of IL-11 in bone marrow failure states. Our preliminary experience with IL-11 at doses of 50 ng/kg/day suggested that bone marrow failure patients developed significant peripheral and pulmonary edema after the prolonged dosing necessary for treating these conditions. We therefore initiated a study of low-dose IL-11 (10 jig/kg/d). Response criteria included doubling of platelets and rise to 50 x lO'/L or tripling of platelets and rise to 20 × 109/L. Sixteen pts are évaluable for response. Their median age was 58 years (range, 5 to 84 years). Six pts had diploid cytogenetics; the others had a variety of chromosomal abnormalities. Six of 16 pts (38%) showed a platelet response to IL-11 and two had a multilineage response (to IL-11 alone (N=l); to IL-11 + G-CSFand EPO (N=l)). Responders included 5 of 11 pts with myelodysplasia (MDS) and 1 of 4 patients with aplastic anemia (AA). Response duration was 12, 13, 14+, 22+, 25 and 30 weeks. Side-effects of IL-11 were mild (peripheral edema, N=7; conjunctival injection, N=7 or myalgia (N=l) (all grade 1). Seven pts had no side-effects. Our pilot study suggests that administration of low dose IL-11 (10μg/kg/day) can raise platelet counts, without significant toxicity, in selected thrombocytopenic patients with bone marrow failure.

AB - Interleukin-11 (IL-11) is a thrombopoietic cytokine that attenuates post-chemotherapy thrombocytopenia. The dose used post-chemotherapy is = 50 ng/kg/day s.c. Very little is known about the activity of IL-11 in bone marrow failure states. Our preliminary experience with IL-11 at doses of 50 ng/kg/day suggested that bone marrow failure patients developed significant peripheral and pulmonary edema after the prolonged dosing necessary for treating these conditions. We therefore initiated a study of low-dose IL-11 (10 jig/kg/d). Response criteria included doubling of platelets and rise to 50 x lO'/L or tripling of platelets and rise to 20 × 109/L. Sixteen pts are évaluable for response. Their median age was 58 years (range, 5 to 84 years). Six pts had diploid cytogenetics; the others had a variety of chromosomal abnormalities. Six of 16 pts (38%) showed a platelet response to IL-11 and two had a multilineage response (to IL-11 alone (N=l); to IL-11 + G-CSFand EPO (N=l)). Responders included 5 of 11 pts with myelodysplasia (MDS) and 1 of 4 patients with aplastic anemia (AA). Response duration was 12, 13, 14+, 22+, 25 and 30 weeks. Side-effects of IL-11 were mild (peripheral edema, N=7; conjunctival injection, N=7 or myalgia (N=l) (all grade 1). Seven pts had no side-effects. Our pilot study suggests that administration of low dose IL-11 (10μg/kg/day) can raise platelet counts, without significant toxicity, in selected thrombocytopenic patients with bone marrow failure.

UR - http://www.scopus.com/inward/record.url?scp=33748652460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748652460&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748652460

VL - 96

SP - 147a

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11 PART I

ER -